Latest news and press releases about PepGen Inc. (PEPG): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Price
| Price | $2.90 |
| Market Cap | $201M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.70 |
| EV / EBITDA | -3.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -51.01% |
| Return on Invested Capital | -56.21% |
| Return on Assets | -50.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CRBP · CRDF · CYBN · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of PEPG: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks